SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Corporate Action-Board approves Dividend
As per letter attached27-05-2020
27-05-2020
Hold Sun Pharmaceutical Industries; target of Rs 436: Prabhudas Lilladher
Prabhudas Lilladher recommended hold rating on Sun Pharmaceutical Industries with a target price of Rs 436 in its research report dated May 21, 2020.23-05-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on May 22, 2020 for Rakesh Sudhir Valia23-05-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on May 20, 2020 for Shanghvi Finance Pvt Ltd21-05-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to the announcement of financial results for the fourth quarter and full-year ending March 31, 202019-05-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Board Meeting Intimation for Consideration And Approval Of Audited Standalone And Consolidated Financial Results Of The Company For The Fourth Quarter And Year Ended On March 31, 2020 And To Consider Recommendation Of Final Dividend For The Year Ended March 31, 2020
SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2020 ,inter alia, to consider and approve (i) To consider and approve Audited Standalone and Consolidated Financial Results of the Company for the fourth quarter and year ended March 31, 2020. (ii) To consider recommendation of final dividend for the year ended March 31, 2020 subject to the approval of the shareholders at the ensuing Annual General Meeting.18-05-2020
Consider short strangle for Sun Pharma
The long-term outlook still remains negative for Sun Pharmaceuticals (Rs 448), as long as it rules below Rs 628. However, the medium-term outlook turn18-05-2020